http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2008127750-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-06 |
| filingDate | 2006-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2008127750-A |
| titleOfInvention | ANTI-VIRUS NUCLEOSIDES |
| abstract | 1. The compound of formula I! ! where! R1 is selected from the group consisting of C2-5 straight or branched alkyl, C2-5 straight or branched alkenyl, C2-5 straight or branched alkynyl, C2-5 lower haloalkyl, C3-6 cycloalkyl and C2-4 alkoxy,! and its hydrates, solvates and acid addition salts. ! 2. The compound according to claim 1, in which R1 is ethyl, n-propyl, isopropyl, n-butyl or isobutyl. ! 3. The compound according to claim 2, in which R1 is ethyl or isopropyl. ! 4. The compound according to claim 1, in which R1 is isopropyl, and the compound is a hydrochloric acid or sulfate salt. ! 5. The compound according to claim 4, which is a hydrochloric acid salt. ! 6. The compound according to claim 1, in which R1 is ethoxy, n-propyloxy or isopropyloxy. ! 7. The compound according to claims 1-6, intended for use in therapy. ! 8. The compound according to claims 1-6, intended for the treatment of diseases mediated by hepatitis C virus (HCV). ! 9. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claims 1-6 in combination with one pharmaceutically acceptable carrier, diluent or excipient. ! 10. The use of the compounds according to claims 1-6 for the preparation of a medicament for the treatment of a disease mediated by hepatitis C virus (HCV). ! 11. The use of claim 10, characterized in that the drug is administered to a patient in need of this in a therapeutically effective dose. ! 12. The use according to claim 10 or 11, characterized in that the drug is administered to a patient in need thereof at a dose of 0.1 to 10 g per day. ! 13. The use of claim 10, characterized in that the drug is administered, together with at least |
| priorityDate | 2005-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.